Jefferies leaves GSK on ‘hold’ – target 1475 pence – 12/07/22 – News

Trade GSK plc shares permanently for 0 euros!

Now on

Drugs in blisters and pharmaceutical bottles (icon image).

© zozzzzo / iStock / Getty Images Plus / Getty Images

NEW YORK (dpa-AFX Analyzer) – The analysis house Jefferies left the rating for GSK on “Hold” with a price target of 1475 pence after a court ruling on alleged cancer risks of the drug Zantac. The court ruling was positive for the two affected pharmaceutical manufacturers GSK and Sanofi, wrote analyst Peter Welford in a study available on Wednesday. It could be seen as a landmark for US federal lawsuits, particularly in the state of Delaware, where a majority of the lawsuits are pending. Study: 12/06/2022 / 5:13 p.m. / ET Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) WpHG, Art. 20 VO (EU) 596/2014 for the named analyst house can be found at http:/ /

A notice: ARIVA.DE publishes analyses, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been posted by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and/or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.